ClinicalTrials.gg
CompletedNCT00656747Updated Dec 1, 2014

Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

A Phase 4 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Amoxicillin clavulanic acid in Chronic Bronchitis, sponsored by Bayer. Completed at 221 sites in 31 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2014-12-01.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,372
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Bronchitis, Chronic with a site in Germany — 2 open to participants now, 4 under way, none of them phase 3. Bronchitis, Chronic · Germany.

Enrollment
4th of 17
1,372 · median 270
Started
2008
with 2 others
Phase 4
3 of 21
none open now
Registered
4th of 21
by date
Lead sponsor
4 of 21
Bayer

Among the 21 studies in Bronchitis, Chronic with a site in Germany, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2008, is one of 3 in phase 4, and was the 4th registered.

Bronchitis, Chronic

209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.

Browse Bronchitis, Chronic studies →

Open to participants now

2 of the 21 studies in Bronchitis, Chronic with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 10 Bronchitis, Chronic studies recruiting now, 5 (50%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Bronchitis, Chronic with a site in Germany, or all of them as a file.
02

Study summary

A study to assess the safety and efficacy of moxifloxacin compared to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbation of chronic bronchitis.

03

Conditions studied

  • Chronic Bronchitis

Keywords

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Acute exacerbation of COPD (AECOPD)
  • chronic bronchitis
  • bronchitis
  • chest infection
  • smoking
  • lung disease
  • lung
  • lungs
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients with chronic bronchitis
  • Male or female subjects, >=60 years old
  • Post bronchodilator (FEV1) less than or equal to 60% predicted and FEV1 / forced vital capacity (FVC) less than 70% at enrollment
  • Documented history of 2 or more AECB episodes, within 12 months of study enrollment, requiring a course of systemic antibiotics and/or systemic
  • All symptoms/signs must be present and confirmed by the Investigator:

    • increase in dyspnea
    • purulent sputum
    • increase in sputum volume
  • Current or past cigarette smoker with equal to or greater than 20 pack year smoking history
  • Subjects must be exacerbation free for at least 30 days prior to enrollment
  • Subjects must be willing and able to complete the questionnaires and subject booklet without assistance

Exclusion criteria

Exclusion Criteria:

  • Known to quinolones, ß lactams, or to any of the of the study drugs
  • Known to have congenital or acquired
  • Known to have bradycardia
  • Known to have clinically relevant heart failure with reduced
  • Known to have previous history of symptomatic arrhythmias
  • Taking QT prolonging drugs, for example Class Ia or III antiarrhythmic agents or other QT prolonging drugs
  • Known electrolyte disturbances that are not controlled, particularly uncorrected hypokalemia
  • Known history of hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose galactose malabsorption
  • History of a tendon disease/disorder
  • Known history of liver dysfunction ( C), including known elevated transaminase levels ( [ALT] and/or aspartate aminotransferase [AST] >5 times the [5 x ULN])
  • Known severe renal impairment with of \<30 mL/min
  • Known neutropenia ( \<1000/mm3) caused by therapy or
  • Known to have Acquired Immunodeficiency Syndrome (AIDS) ( of \<200/mm3), or be (HIV) positive and receiving highly active anti retroviral therapy (HAART) (testing for HIV is not mandatory)
  • Known chronic asthma (>15% reversibility or at least 200 mL), bronchial carcinoma, active pulmonary tuberculosis, known diffuse bronchiectasis, cystic fibrosis, or pneumonia (a chest x ray is not mandatory)
  • Known history of chronic colonization of pathogenic organisms resistant to moxifloxacin and/or amoxicillin clavulanic acid (eg, P. aeruginosa, methicillin resistant Staphylococcus aureus)
  • Receiving long term (>4 consecutive weeks) systemic treatment (>10 mg/day of prednisolone or equivalent)
  • Received short course of systemic corticosteroid treatment within 30 days prior to enrollment
  • of less than 6 months
  • Receiving systemic antibacterial therapy within 30 days prior to study enrollment
  • Requiring concomitant systemic antibacterial agents
  • Requiring home ventilatory support (subjects requiring home/portable oxygen therapy or continuous positive airway pressure (CPAP) for sleep apnea are not excluded) and/or those who have a tracheotomy in situ
  • History of liver function disorders following previous treatment with amoxicillin-clavulanic acid
  • Receiving disulfiram therapy
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,372 participants (actual)

Study arms

  • Active comparator
    Arm 2

    Drug: Amoxicillin clavulanic acid

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

Interventions

  • Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.

  • Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.

06

What researchers measure

Primary outcomes

  1. Clinical failure at 8 weeks post therapy

    Time frame: At day 63

Secondary outcomes

  1. Clinical failure rates

    Time frame: Through to day 35

  2. Bacteriological eradication rates

    Time frame: Through to day 63

  3. Clinical failure rates for subjects with positive sputum culture at enrollment

    Time frame: Through to day 63

  4. Weekly mean symptom scores measured by the AECB SS

    Time frame: Through to day 63

  5. Rates and speed of symptom relief measured by the AECB SS

    Time frame: Through to day 63

  6. Clinical failure rates for subjects with co-administration of systemic corticosteroids (stratum 1)

    Time frame: Through to day 63

  7. Clinical failure rates for subjects without co-administration of systemic corticosteroids (stratum 2)

    Time frame: Through to day 63

  8. Need for any change in dosage or additional respiratory medication such as bronchodilators and inhaled steroids, excluding short acting bronchodilators

    Time frame: Through to day 63

  9. Improvement in symptoms burden measured by the AECB SS

    Time frame: Through to day 63

  10. Improvement in health related QoL measured by the SGRQ

    Time frame: Through to day 63

  11. spirometry tests will be compared between treatment groups

    Time frame: Through to day 63

  12. HCRU relat. to chronic bronchitis management incl. rescue med., concomitant med., therap. adjuncts, diagn. procedures, other medical care/medical staff requirement, hospitalizations (incl. ward and duration), and work productivity and activity impairment

    Time frame: Through to day 63

  13. Safety and tolerability of moxifloxacin versus amoxicillin clavulanic acid, with particular attention to rates of diarrhea

    Time frame: Through to day 63

07

Study locations

221 sites
  • Escaldes - Engordany, Andorra
  • Florencio Varela, Buenos Aires, Argentina
  • Quilmes, Buenos Aires, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires 1426, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1424BSF, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1425AWC, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
  • San Miguel de Tucumán, Tucuman 4000, Argentina
  • San Miguel de Tucumán, Tucuman, Argentina
  • Vicente López, 1638, Argentina
  • Concord, New South Wales 2139, Australia
  • Brisbane, Queensland 4101, Australia
  • Adelaide, South Australia 5041, Australia
  • Woodville, South Australia 5011, Australia
  • Nedlands, Western Australia 6009, Australia
  • Aalst, 9300, Belgium
  • Antwerpen, 2018, Belgium
  • Bruxelles - Brussel, 1020, Belgium
  • Halen, 3545, Belgium
  • Lommel, 3920, Belgium
  • Moerkerke, 8340, Belgium
  • Namur, 5000, Belgium
  • Yvoir, 5530, Belgium
  • Juiz de Fora, Minas Gerais 36036-110, Brazil
  • Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • São Paulo, Sao Paulo 04032-060, Brazil
  • São Paulo, Sao Paulo 05403-900, Brazil
  • Calgary, Alberta T2N 4Z6, Canada
  • Edmonton, Alberta T6G 2B7, Canada
  • Edmonton, Alberta T6L 5X8, Canada
  • Kelowna, British Columbia V1Y 8E7, Canada
  • Vancouver, British Columbia V5Z 4E1, Canada
  • Winnipeg, Manitoba R3A 1R8, Canada
  • Winnipeg, Manitoba R3C 0N2, Canada
  • Saint John, New Brunswick E2K 2T8, Canada
  • Saint John, New Brunswick E2M 3W5, Canada
  • Antigonish, Nova Scotia B2G 2C2, Canada
  • Sydney Mines, Nova Scotia B1V 2Y5, Canada
  • Burlington, Ontario L7R 3X4, Canada
  • Hamilton, Ontario L8N 4A6, Canada
  • London, Ontario N6A 4V2, Canada
  • London, Ontario N6A 5G6, Canada
  • Toronto, Ontario M6H 3M2, Canada
  • Longueuil, Quebec J4N 1E1, Canada
  • Montreal, Quebec H2L 4M1, Canada
  • Sherbrooke, Quebec JIH 4J6, Canada
  • Santiago, Chile
  • Valparaíso, Chile
  • Viña del Mar, Chile
  • Guangzhou, Guangdong 510120, China
  • Guangzhou, Guangdong 510405, China
  • Changsha, Hunan 410013, China
  • Shengyang, Liaoning 110004, China
  • Shenyang, Liaoning 110001, China
  • Chengdu, Sichuan 610041, China
  • Beijing, 100020, China
  • Beijing, 100050, China
  • Shanghai, 200003, China
  • Shanghai, 200040, China
  • Shanghai, 200233, China
  • Tianjin, 300052, China
  • Cali, Cauca, Colombia
  • Bogotá, Colombia
  • Bucaramanga, Colombia
  • Cali, Colombia
  • Medellín, Colombia
  • Santafe de Bogotá, Colombia
  • Osijek, 310 00, Croatia
  • Petrinja, 44 250, Croatia
  • Rijeka, 510 00, Croatia
  • Zagreb, 10000, Croatia
  • Kyjov, 697 01, Czech Republic
  • Lovosice, 410 02, Czech Republic
  • Neratovice, 227 11, Czech Republic
  • Pardubice - Trnova, 530 09, Czech Republic
  • Praha - Malesice, 108 00, Czech Republic
  • Praha - Troja, 182 00, Czech Republic
  • Marseille, 13009, France
  • Mont-de-marsan, 40000, France
  • Nice, 06000, France
  • Perpignan, 66025, France
  • Bad Dürrheim, Baden-Württemberg 78073, Germany
  • Augsburg, Bayern 86150, Germany
  • Cottbus, Brandenburg 03050, Germany
  • Rüdersdorf, Brandenburg 15562, Germany
  • Zossen, Brandenburg 15806, Germany
  • Frankfurt, Hessen 60318, Germany
  • Frankfurt, Hessen 60389, Germany
  • Fulda, Hessen 36039, Germany
  • Neubrandenburg, Mecklenburg-Vorpommern 17033, Germany
  • Lüdenscheid, Nordrhein-Westfalen 58515, Germany
  • Neuwied, Rheinland-Pfalz 56564, Germany
  • Böhlen, Sachsen 04564, Germany
  • Delitzsch, Sachsen 04509, Germany
  • Dresden, Sachsen 01307, Germany
  • Leipzig, Sachsen 04207, Germany
  • Leipzig, Sachsen 04275, Germany
  • Leipzig, Sachsen 04357, Germany
  • Meißen, Sachsen 01662, Germany
  • Bad Segeberg, Schleswig-Holstein 23795, Germany

Showing the first 100 of 221 sites across 31 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Wilson R, Anzueto A, Miravitlles M, Arvis P, Farago G, Haverstock D, Trajanovic M, Sethi S. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J Chron Obstruct Pulmon Dis. 2011;6:373-83. doi: 10.2147/COPD.S21071. Epub 2011 Jun 29. PubMed 21760724 ↗
  • Wilson R, Anzueto A, Miravitlles M, Arvis P, Haverstock D, Trajanovic M, Sethi S. Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2015 Jun 2;10:985-93. doi: 10.2147/COPD.S80926. eCollection 2015. PubMed 26082623 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2008
First posted
Apr 11, 2008
Start
Mar 2008
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Last update
Dec 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00656747
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 11, 2008
Start date
Mar 2008
Primary completion
Dec 2010
Completion
Dec 2010
Last update
Dec 1, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion